Hosts with compromised or naive immune systems, such as individuals living with HIV/AIDS,
transplant recipients, and fetuses, are at the highest risk for complications from …

The recent approval of letermovir marks a new era of therapy for human cytomegalovirus
(HCMV) infections, particularly for the prevention of HCMV disease in hematopoietic stem …

Cytomegalovirus (CMV) infection can have both direct and indirect effects after solid-organ
transplantation, with a significant impact on transplant outcomes. Prevention strategies …

Organ transplant recipients (OTRs) are a population at high risk for cutaneous adverse
events. Their early recognition and appropriate treatment is an important component of the …

Cytomegalovirus (CMV) is one of the most important opportunistic infections in solid organ
transplant (SOT) recipients. However, current techniques used to predict risk for CMV …

Background Cryptococcal meningitis and tuberculosis are both important causes of death in
persons with advanced human immunodeficiency virus (HIV)/acquired immunodeficiency …

Objectives CMV viremia is associated with increased mortality in persons with HIV. We
previously demonstrated that CMV viremia was a risk factor for 10-week mortality in …

Human cytomegalovirus (CMV) infection, which is one of the most common complications in
transplant recipients, increases the risk of graft loss and rejection. Laboratory strategies for …

Letermovir is an effective antiviral agent for CMV prevention and has demonstrated
enhanced safety, which may allow for extended durations of primary prophylaxis among …

The next frontier: cytomegalovirus antiviral stewardship pro... : Current Opinion in Infectious
Diseases The next frontier: cytomegalovirus antiviral stewardship programs in solid organ …